ARCT offers highly asymmetric speculative upside as Vertex’s VX-522 exit leaves ARCT-032 alone in inhaled mRNA CF, but clinical failure, CSL disruption and dilution remain material risks.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage biotechnology company specializing in the development of messenger RNA (mRNA) medicines focused on rare liver and respiratory diseases.[1, 2] The company maintains a proprietary technological foundation consisting of its LUNAR lipid-mediated delivery platform, which targets intracellular transport of nucleic acids, and its STARR self-amplifying mRNA (sa-mRNA) technology, which allows for prolonged protein expression at lower therapeutic doses.[1, 2] Arcturus operates at the intersection of genetic medicine and commercial drug development, transitioning from a historical focus on infectious disease vaccines toward high-value orphan drug indications.[3, 4]
The company generates revenue through multiple clinical and commercial streams, including strategic alliances, research collaborations, license fees, consulting and technology transfer arrangements, and non-dilutive government contracts.[5, 6] Geographically, the corporate footprint spans the United States, Europe, and Japan.[2, 7] Key operational relationships include its development and commercialization partnership with CSL Seqirus for pandemic vaccines [2], a joint venture in Japan under the entity ARCALIS for clinical and commercial mRNA manufacturing [2, 8], and a manufacturing and clinical research collaboration with Thermo Fisher Scientific.[9, 10] Arcturus also secures non-dilutive contract funding from the United States Biomedical Advanced Research and Development Authority (BARDA) to advance pandemic preparedness assets.[7, 11]
The core pipeline of Arcturus consists of two primary clinical-stage therapeutic programs.[11, 12] The first is ARCT-032, an inhaled mRNA therapeutic candidate delivering a corrective transcript of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene directly to the lungs of patients with cystic fibrosis.[13, 14] This candidate is specifically designed for Class I (null) mutation patients who do not produce any baseline CFTR protein and are thus ineligible for existing small-molecule modulators.[13, 15] The second is ARCT-810, an intravenously administered LUNAR-encapsulated mRNA therapeutic delivering a functional ornithine transcarbamylase (OTC) gene to hepatocytes to treat systemic OTC deficiency.[16, 17] On the commercial front, the company developed KOSTAIVE, the world's first approved sa-mRNA COVID-19 vaccine, commercialized in Japan through Meiji Seika Pharma.[2, 3]
| Primary Clinical & Commercial Assets | Technology Platform | Target Indication | Target Customers / Partners | Geographies |
|---|---|---|---|---|
| ARCT-032 | Inhaled LUNAR mRNA | Class I Cystic Fibrosis | Thermo Fisher, Cystic Fibrosis Foundation [4, 9] | Global (US/Europe/RoW) [3] |
| ARCT-810 | Intravenous LUNAR mRNA | Ornithine Transcarbamylase Deficiency | Fully-Owned Pipeline Asset [4] | Global (US/Europe/RoW) [11] |
| KOSTAIVE | STARR sa-mRNA Vaccine | COVID-19 Immunization | Meiji Seika Pharma, CSL Seqirus [2, 3] | Japan, Europe [3, 4] |
Arcturus’ competitive advantage stems from the unique chemical architecture of its LUNAR lipid delivery system.[3] Unlike conventional lipid nanoparticles (LNPs) developed by competitors, which have historically triggered localized lung inflammation and dose-limiting toxicities when delivered repeatedly, Arcturus’ proprietary ionizable lipids are chemically distinct, demonstrating rapid clearance and an excellent tolerability profile.[3, 15] This allows for chronic, repeated administration without the requirement for corticosteroid pre-treatment.[3, 18, 19] Partners and clinicians select Arcturus’ platform over alternatives because it solves the fundamental therapeutic bottleneck of repeated LNP dosing in delicate pulmonary tissues.[3, 15]
Arcturus Therapeutics operates a hybrid business model that commercializes proprietary intellectual property while retaining long-term economic participation in downstream drug sales.[5, 9] The company is actively licensing its LUNAR and STARR platforms to pharmaceutical developers, offering custom chemical synthesis, lipid formulation development, and clinical-stage manufacturing support.[1, 5] The core strategic value rests on three primary pillars:
The competitive moat protecting Arcturus’ business model is anchored by its extensive intellectual property portfolio, significant customer switching costs, and regulatory exclusivity.[1, 2, 14] The company holds over 500 patents and pending patent applications globally, covering novel ionizable lipids, lipid-to-mRNA ratios, sa-mRNA replicon designs, and specialized manufacturing techniques.[1, 2] A key structural differentiator for Arcturus is the uncontested nature of its IP; while peers in the mRNA space remain locked in complex, multi-district litigation over fundamental LNP technology, Arcturus has avoided the "mRNA patent wars" entirely.[4]
Additionally, switching costs are exceptionally high.[9, 10] Once a CDMO partner like Thermo Fisher Scientific integrates Arcturus’ specific lipid formulations into its Patheon manufacturing lines or utilizes its PPD clinical research services for a multi-year Phase III trial, the operational, technological, and regulatory costs of switching to an alternative delivery platform are prohibitively high.[9, 10] This operational integration creates a deeply entrenched development ecosystem, securing Arcturus’ role as a long-term commercial supplier.[9, 14]
Arcturus’ strategic redirection toward rare diseases addresses high-value, orphan-drug indications characterized by severe unmet medical needs, limited competition, and favorable pricing dynamics.[3, 16, 20]
| Indication / Segment | Target Patient Population | Global Market Size Projection | Growth CAGR | Estimated Annual Treatment Cost |
|---|---|---|---|---|
| Class I Cystic Fibrosis | ~10% of the 100,000–160,000 global CF population (approx. 10,000–16,000 patients) [14, 15, 21] | Total CF market projected to reach $26.58 Billion by 2031 [21] | 11.8% (2024–2031) [21] | Small-molecule modulators benchmarked at $300,000+ per patient annually [21, 22] |
| Ornithine Transcarbamylase Deficiency | ~10,000 patients across the US and Europe; incidence of 1 in 56,000 births [16, 23] | Global OTCD treatment market projected to reach $1.08 Billion by 2031 [23] | 4.13% to 4.50% (2026–2033) [23, 24] | Standard nitrogen scavengers (e.g., Ravicti) cost up to $793,632 per patient annually [24] |
The competitive dynamics of the inhaled genetic pulmonary market changed fundamentally in early 2026.[15, 25] Historically, the primary competitive threat to ARCT-032 was VX-522, an inhaled CFTR mRNA candidate co-developed by Vertex Pharmaceuticals and Moderna.[15, 25] However, on May 4, 2026, Vertex announced the complete clinical discontinuation of the VX-522 program during its Phase I/II trial due to persistent tolerability issues, specifically localized lung inflammation caused by Moderna's LNP delivery vehicle.[15, 26] This leaves ARCT-032 as the uncontested leader in inhaled mRNA therapeutics for cystic fibrosis, positioned to capture the entire Class I null mutation segment that cannot benefit from Vertex’s dominant small-molecule modulators, Trikafta and Alyftrek.[9, 15, 22]
In the OTC deficiency segment, standard of care remains limited to strict dietary protein restriction and oral nitrogen scavengers, which fail to address the underlying enzymatic defect and carry high economic burdens.[16, 24] While competing gene therapy and gene-editing programs (such as iECURE) are in development, they face severe enrollment constraints and safety concerns.[23, 24] Arcturus has established a significant head start, presenting clinical Phase II data that demonstrates sustained reductions in blood glutamine levels and statistically significant increases in relative ureagenesis function (RUF) in patients treated with ARCT-810.[18, 19]
To capitalize on these advantages, Arcturus signed a milestone $80 million strategic collaboration with Thermo Fisher Scientific on June 26, 2026.[9, 10] The contract splits into a $40 million commitment for clinical manufacturing and scale-up through Thermo Fisher’s Patheon unit, and a $40 million commitment for clinical trial execution through its PPD clinical research business to advance ARCT-032 into Phase III trials.[9, 10] This partnership leverages Thermo Fisher's global infrastructure, mitigating clinical execution risks and establishing a clear path toward commercial launch.[9, 14]
Arcturus reported its financial results for the first quarter of fiscal year 2026 (ended March 31, 2026) on May 7, 2026.[6, 27]
The company posted total revenue of $2.06 million, down 92.99% from $29.38 million in the first quarter of 2025.[6, 27] This performance fell significantly short of consensus Wall Street expectations, missing the average analyst estimate of $6.30 million by $4.24 million (representing an ~67% top-line miss).[6, 27, 28]
For the quarter ended March 31, 2026, Arcturus reported a net loss of $27.0 million, or $(0.95) per diluted share, compared to a net loss of $14.1 million, or $(0.52) per diluted share, in the comparable prior-year period.[6] This bottom-line result beat consensus analyst expectations of $(1.01) per share by $0.06, primarily due to disciplined expense management and a reduction in clinical trial costs for legacy vaccine programs.[3, 6, 27]
| Financial Metrics (USD in Thousands) | Q1 2026 (Unaudited) | Q1 2025 (Unaudited) | YoY % Change | Performance vs. Consensus |
|---|---|---|---|---|
| Collaboration Revenue | $610 | $25,477 | -97.61% | Missed Expectations [6, 7] |
| Grant Revenue | $1,451 | $3,905 | -62.84% | Declining as expected [6, 7] |
| Total Revenue | $2,061 | $29,382 | -92.99% | Missed by $4,240 USD [6, 27] |
| R&D Expense, Net | $21,527 | $34,893 | -38.31% | Lower due to LUNAR-COVID wind-down [3, 6] |
| G&A Expense | $9,465 | $11,315 | -16.35% | Reduced headcount & SBC [6] |
| Net Loss | $26,964 | $14,076 | +91.56% | Widened on lower revenues [6] |
| Diluted EPS (in USD) | $(0.95) | $(0.52) | +82.69% | Beat consensus by $0.06 USD [6, 27] |
| Cash and equivalents | $213,403 | $232,800* | -8.33% | Runway confirmed past Q2 2028 [6] |
*Balance as of December 31, 2025. [6]
As of March 31, 2026, Arcturus maintained cash, cash equivalents, and restricted cash of $213.40 million, compared to $232.80 million as of December 31, 2025.[6] Operating liabilities remained manageable, with total current liabilities of $34.37 million (including accounts payable of $4.09 million and accrued liabilities of $22.67 million) and total liabilities of $54.05 million against stockholders' equity of $191.36 million.[6] The accumulated deficit stood at $541.55 million.[6]
Arcturus did not alter its operational guidance, confirming that its existing cash reserves are sufficient to support all planned clinical development and regulatory milestones beyond the second quarter of 2028, representing a cash runway of over two and a half years.[3, 6] No formal revenue guidance was provided, as partner Meiji holds exclusive commercial guidance rights for KOSTAIVE commercialization in Japan.[3]
During the earnings call, CEO Joseph Payne highlighted a major operational pivot: the enrollment of the 12-week Phase II cystic fibrosis study was initiated ahead of schedule in Q1 2026, and patients had successfully surpassed one month of continuous inhaled dosing.[3, 11] This continuous dosing duration represents a key clinical milestone, as no other inhaled mRNA therapeutic has been tolerated beyond a month without triggering severe inflammatory safety events.[3]
Additionally, Chief Medical Officer Dr. Alan Cohen confirmed that the FDA provided clear regulatory direction on a clinical pathway toward a pivotal pediatric study for ARCT-810.[3, 6]
The immediate market impact of the Q1 2026 results was characterized by near-term negative adjustments in analyst sentiment.[28] Following the steep revenue miss, the covering analyst consensus price target was trimmed by 12% from $23.30 down to $20.40, reflecting a reduction in short-term COVID-19 milestone assumptions.[12, 28]
However, this negative revision was rapidly offset on July 2, 2026, when Arcturus announced the Thermo Fisher collaboration.[9] The de-risking impact of the $80 million commitment triggered a significant technical reversal, with the stock rallying 5.7% to close at $7.28 on July 3, 2026.[9, 29]
To evaluate Arcturus’ intrinsic value, investors must look beyond traditional, backward-looking trailing valuation multiples.[28] While the company achieved an impressive 5-year compound annual growth rate (CAGR) in recognized revenues of 53.8% from FY20 ($9.54 million) to FY25 ($82.03 million), this growth was driven entirely by non-recurring vaccine milestone inflows.[30, 31]
$\text{5-Year Revenue CAGR} = \left(\frac{\$82.03\text{ Million}}{\$9.54\text{ Million}}\right)^{\frac{1}{5}} - 1 = 53.8\% \quad [31]$
Because the company is currently unprofitable and transitioning its business model, its valuation is driven by the risk-adjusted Net Present Value (rNPV) of its clinical candidates.[32] The primary financial drivers that determine long-term valuation include:
Evaluating Arcturus' long-term investment profile requires an analysis of company-specific, industry-wide, and macroeconomic risk factors:
Arcturus Therapeutics Risk Mapping Matrix
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
| Risk Category | What Could Go Wrong | Early Warning Sign | Long-Term Thesis Impact |
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
| Clinical Execution | ARCT-032 fails to show lung | Safety board requests clinical | Inhaled LUNAR platform is proven |
| | function improvement in Phase II. | dose-escalation pauses. [3] | clinically unviable. [3, 15]|
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
| Competitive / Industry | Gene therapy/editing achieves | Competitor trials post high rates | OTCD chronic bi-weekly dosing is |
| | a permanent cure for OTCD. | of permanent cure. [23] | commercially obsolete. [23] |
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
| Customer Concentration | CSL Seqirus partnership | Continued unpaid milestone | Complete loss of legacy vaccine |
| | dissolves under arbitration. | disputes in courts. [4] | funding and partner backing. [4]|
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
| Legal & Regulatory | FDA delays pediatric Phase III | Delays in securing EOP2 meeting | Prolonged trial timelines exhaust |
| | trial guidelines for ARCT-810. | alignment in H2 2026. [3] | existing cash reserves. [6] |
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
| Balance Sheet | Accelerated Phase III burn rate | Cash balance falls below $100M | Dilutive equity issuance at a |
| | exhausts $213.4M cash runway. | with no licensing deal. [6] | depressed stock price. [4] |
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
| Macroeconomic | Inflation increases trial costs; | Rising per-patient clinical site | Squeezes margins and shortens |
| | reimbursement pushback. [20] | operational overhead. [20] | corporate runway. [6] |
+---------------------------+-----------------------------------+-----------------------------------+-----------------------------------+
In clinical execution, the primary concern is that continuous dosing of ARCT-032 or ARCT-810 could trigger long-term toxicity or fail to demonstrate clinical benefit.[3, 32] What could go wrong is a failure of ARCT-032 to show meaningful improvement in ppFEV1 or lung clearance index (LCI) in the Phase II trial, or the emergence of chronic pulmonary congestion.[3, 6]
An early warning sign would be safety monitoring board interventions, dosing pauses, or the introduction of corticosteroid pre-treatments.[3, 19] What would most damage the thesis is a complete clinical termination of ARCT-032 due to toxicity, which would invalidate the pulmonary delivery application of the LUNAR platform.[3, 15]
From a competitive standpoint, although Vertex discontinued its competing mRNA program, it is actively developing alternative technologies, such as the gene-editing candidate VX-828.[15, 22] In the OTC deficiency space, competitors are advancing one-time gene therapies and in-vivo gene-editing platforms.[23, 24] What could go wrong is a competitor achieving permanent gene correction, eliminating the market for Arcturus' chronic, bi-weekly intravenous therapy.[16, 23, 33]
An early warning sign would be accelerated regulatory reviews or high cure-rate data from competitor Phase II gene-editing trials.[23, 24] What would most damage the thesis is the market launch of a safe, one-time cure for OTCD, rendering ARCT-810 obsolete.[16, 23]
Arcturus faces severe customer concentration, with CSL Seqirus accounting for approximately 84% of its recognized revenue over the last four years.[4] This relationship has deteriorated.[4] In May 2025, Arcturus initiated arbitration against CSL over unpaid milestones, and CSL subsequently recorded a massive $430 million write-down of the collaboration, writing off the entire book value of the associated IP.[4] CSL has halted seasonal influenza trials and refused to commercialize KOSTAIVE in Europe.[4, 7]
What could go wrong is a formal termination of the CSL partnership, leaving KOSTAIVE stranded globally.[4, 7] An early warning sign would be prolonged legal gridlock or Meiji cutting its Japanese distribution agreements.[3, 4] What would most damage the thesis is a complete dissolution of the partnership with no replacement, depriving Arcturus of legacy vaccine cash flows.[4, 7]
On the regulatory front, changes in FDA or EMA requirements can delay clinical progress.[4, 20] For example, a September 2025 FDA policy change led Arcturus to classify the US approval of KOSTAIVE as indefinitely delayed.[4] Financially, the company's cash runway of $213.4 million must support late-stage trials.[6] What could go wrong is a clinical delay that extends Phase III trials, exhausting cash reserves before commercialization.[6]
An early warning sign would be an acceleration of net cash burn above $35 million per quarter.[6] What would most damage the thesis is the company being forced to raise capital through highly dilutive equity offerings at a depressed stock price, significantly reducing upside for existing shareholders.[4]
Arcturus is highly sensitive to macroeconomic shifts, particularly inflation and the high cost of clinical operations.[6, 20] High interest rates and clinical site inflation increase the cost per patient, reducing the purchasing power of the cash balance.[6, 20]
Additionally, orphan drugs face reimbursement pushback.[20, 21] In an economic downturn, insurance payers may restrict access to high-cost therapies, limiting the addressable market for ARCT-032 and ARCT-810.[20, 21, 24]
To project Arcturus' potential valuation over a 5-year investment horizon (ending FY2031), three operational scenarios are modeled based on clinical progress, commercial execution, and dilutive capital requirements.
All projections are priced in US Dollars (USD).[34] Calculations utilize the following valuation formula:
$\text{Projected Share Price} = \frac{\text{Projected Revenue} \times \text{Projected Net Margin} \times \text{Exit P/E Multiple}}{\text{Fully Diluted Share Count}}$
The Base Case assumes that ARCT-032 successfully navigates Phase II trials, transitioning to a registrational Phase III study managed by PPD and manufactured by Patheon under the Thermo Fisher MSA.[9, 10] By FY2031, ARCT-032 is approved in the US and Europe for Class I CF mutations, capturing a conservative 20% of the eligible 10,000-patient market (2,000 patients).[14, 15]
Priced at $250,000 annually, this generates $500 million in gross sales, resulting in $150 million in high-margin royalty/milestone revenue for Arcturus.[21, 22] Concurrently, ARCT-810 is approved for severe pediatric OTC deficiency, capturing 400 patients globally at a price of $250,000 per year, yielding $100 million in commercial revenue.[16, 24] KOSTAIVE commercial sales in Japan remain stable via Meiji, contributing a modest $20 million.[3]
The High Case assumes a rapid clinical development timeline. Following Vertex's exit, ARCT-032 is granted accelerated approval, capturing a dominant 35% of the Class I mutation market and expanding into a broader non-modulator CF population (totaling 4,000 patients).[14, 15] This drives $300 million in high-margin revenue to Arcturus.[21] ARCT-810 captures 800 patients globally, generating $200 million in revenue.[16, 24]
Importantly, Arcturus resolves its arbitration with CSL, receiving a $100 million settlement, and licenses its uncontested LUNAR delivery platform to a major pharmaceutical player for oncology applications, generating an upfront payment of $500 million (recognized as $100 million annually over 5 years).[4]
The Low Case assumes clinical failure.[32] ARCT-032 fails to show efficacy or triggers unexpected inflammatory reactions during the 12-week Phase II trial, halting development entirely.[3, 15] Concurrently, the FDA end of Phase II meeting for ARCT-810 is delayed, and a competitor's pediatric gene-editing program successfully demonstrates curative endpoints, severely limiting ARCT-810's addressable market.[3, 24]
The CSL partnership is terminated, and KOSTAIVE sales in Japan collapse as seasonal booster demand evaporates.[4, 7] Arcturus is forced to downsize operations, relying on its BARDA grant to survive while running highly dilutive capital raises to fund early-stage pre-clinical research.[4, 7]
The projected share price path under each scenario illustrates the potential valuation development:
| Scenario | Year 0 (Current) [34] | Year 1 (FY2027) | Year 2 (FY2028) | Year 3 (FY2029) | Year 4 (FY2030) | Year 5 (FY2031) |
|---|---|---|---|---|---|---|
| High Case | $7.39 | $18.00 | $35.00 | $60.00 | $95.00 | $142.11 |
| Base Case | $7.39 | $10.00 | $14.00 | $19.00 | $24.00 | $30.00 |
| Low Case | $7.39 | $5.00 | $3.00 | $1.50 | $0.80 | $0.50 |
Integrating these three scenarios using their subjective probabilities yields the weighted future share price:
$\text{Weighted Price} = (0.50 \times \$30.00) + (0.20 \times \$142.11) + (0.30 \times \$0.50) = \$15.00 + \$28.42 + \$0.15 = \$43.57\text{ USD}$
This probability-weighted share price of $43.57 USD indicates significant asymmetric upside from the current share price of $7.39, driven by the clinical differentiation of ARCT-032 following Vertex's retreat.[15, 34]
Five-Year Scenario Matrix (All Share Prices in USD)
+----------+------------+------------+------------+---------+------------+----------+------------+-------------+
| Scenario | Yr 5 Rev | Net Margin | Exit Mult | Cur. SP | Implied SP | Total Rtn| Ann. Rtn | Probability |
+----------+------------+------------+------------+---------+------------+----------+------------+-------------+
| High | $600.0M | 30.0% | 30.0x P/E | $7.39 | $142.11 | 1823.00% | 80.68% | 20.0% |
| Base | $270.0M | 20.0% | 25.0x P/E | $7.39 | $30.00 | 305.95% | 32.34% | 50.0% |
| Low | $30.0M | N/A | 1.0x P/S | $7.39 | $0.50 | -93.23% | -41.60% | 30.0% |
+----------+------------+------------+------------+---------+------------+----------+------------+-------------+
ASYMMETRIC RISK-REWARD
Rating Arcturus Therapeutics on its core organizational and commercial attributes on a scale of 1 to 10 highlights its key strengths and challenges:
$\text{Blended Score} = \frac{8+4+8+8+6+7+7+8+2+6}{10} = 6.4 \ / \ 10$
This analysis provides a comprehensive qualitative assessment of Arcturus’ business model but is for informational purposes only and does not contain financial advice or investment recommendations.
HIGH SPECULATIVE POTENTIAL
The investment thesis for Arcturus Therapeutics is defined by its transition from a volatile vaccine business to an enterprise focused on high-value, orphan genetic diseases.[3, 4] The company’s core valuation driver is the uncontested leadership of ARCT-032 in the Class I cystic fibrosis segment following the clinical exit of Vertex's VX-522.[9, 15] This is supported by the unique tolerability profile of the LUNAR LNP platform, which has achieved unprecedented repeated dosing milestones in delicate lung tissue.[3]
Near-term catalysts include Phase II lung function readouts (ppFEV1 and LCI) for ARCT-032 in late 2026, alongside regulatory alignment at the H2 2026 End of Phase II meeting with the FDA to initiate a pivotal pediatric trial for ARCT-810.[3, 11] Although risks remain regarding cash burn and the arbitration with CSL, the $80 million partnership with Thermo Fisher significantly de-risks late-stage development.[4, 9, 10]
At its current share price, the stock represents an attractive risk-reward opportunity for investors seeking exposure to genetic medicine, as the market’s focus on declining COVID-19 vaccine revenues has obscured the value of Arcturus’ rare disease pipeline.[28, 29, 34] This analysis provides a summary of the business profile and pipeline trajectory and is strictly for informational purposes, containing no financial advice or recommendations.
TRANSITIONAL PIPELINE PIVOT
Arcturus is trading at $7.39, consolidating directly above its simple 200-day moving average of $7.33 and its exponential 200-day moving average of $7.39.[34, 38] Technical indicators are constructive, with the MACD holding in positive territory at 0.11 and the RSI at 55.7, indicating steady accumulation and low volatility.[38]
The stock has established a solid support floor near its 52-week low of $5.85, showing strong technical recovery following the announcement of the Thermo Fisher partnership.[9, 29, 34]
In the short term, the share price is expected to trade within the $5.86 to $9.34 range, with potential upward momentum as the market anticipates Phase II clinical readouts in the second half of 2026.[3, 39] This technical overview is provided for analytical purposes only and does not constitute financial advice.
BULLISH TREND CONTINUANCE
View Arcturus Therapeutics Holdings Inc. (ARCT) stock page
Loading the interactive version of this report…